Eli Lilly's tirzepatide is off FDA's shortage list
Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Eli Lilly (NYSE:LLY) has partnered with the British ... tirzepatide, branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.